107.00Open107.00Pre Close0 Volume49 Open Interest150.00Strike Price0.00Turnover102.19%IV9.70%PremiumJan 17, 2025Expiry Date84.28Intrinsic Value100Multiplier12DDays to Expiry22.72Extrinsic Value100Contract SizeAmericanOptions Type0.9934Delta0.0004Gamma2.77Leverage Ratio-0.0477Theta0.0499Rho2.75Eff Leverage0.0080Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet